Sensory NeuroStimulation, Inc. (dba as Relaxis), San Clemente, Calif.-based makers of a device for treating Restless Legs Syndrome (RLS), has entered into a $1.5m credit facility agreement with Silicon Valley Bank.
The company will use the proceeds for ongoing operations as it launches its Relaxis system.
Led by Chairman Fred Burbank, M.D., Sensory NeuroStimulation has developed the Relaxis system, the first and only FDA-cleared, non-pharmacologic solution for improving the quality of sleep in patients with primary RLS, a progressive neurological condition also known as Willis-Ekbom Disease (WED).
The Relaxis device was designed to provide physical relief of RLS symptoms through the use of vibratory counterstimulation, and is available on a prescription-only basis in the U.S.
FinSMEs
14/01/2015